You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Suspected cancer: recognition and referral

  • NICE guideline
  • Reference number: NG12
  • Published:  23 June 2015
  • Last updated:  15 April 2026
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download (PDF)

Evidence reviews

The following documents contain the evidence that was used to develop the 2026 recommendations:

  • Dual testing with serum CA125 and ultrasound scan compared to serum CA125 alone and age and serum CA125 thresholds for detection of suspected ovarian cancer in adults
  • Technical appendices for dual testing with serum CA125 and ultrasound scan compared to serum CA125 alone and age and serum CA125 thresholds for detection of suspected ovarian cancer in adults
  • Endometrial cancer: unscheduled bleeding, HRT and cancer referral
  • Technical appendices for endometrial cancer: unscheduled bleeding, HRT and cancer referral
  • Unexplained weight loss as a non-site specific symptom in adults in primary care
  • Technical appendices for unexplained weight loss as a non-site specific symptom in adults in primary care

The following document contains the evidence that was used to develop the 2021 recommendations:

  • Diagnostic accuracy of prostate specific antigen (PSA) thresholds for referring people with suspected prostate cancer

Other supporting evidence

  • Full guideline
  • Appendices A to E
  • Appendix F
  • Appendix G
  • Appendix H
  • Appendix I
  • Appendix J1
  • Appendix J2
  • Appendix J3
  • Appendix J4

This page was last updated: 15 April 2026

Back to top